Novel dry and emulsified oil formulations of Metarhizium and Beauveria mycoinsecticides that improve spore viability, stability, and shelf life for commercial seed treatment applications in agriculture and turfgrass.
This research addresses a critical barrier to commercial adoption of entomopathogenic fungi (EPF) as biological seed treatments for insect pest control. Metarhizium and Beauveria are naturally occurring insect-killing fungi with significant potential as sustainable alternatives to chemical pesticides, but their sensitivity to hydration and dehydration has historically caused rapid loss of spore viability, limiting practical use. The proposed solution combines dry powder and emulsified oil formulations with conventional water-based seed coating processes, enabling co-application with standard seed treatments while protecting fungal spores. The result is improved loading capacity, application uniformity, and extended shelf life—key factors for integrating biological controls into mainstream seed treatment workflows in row crops and turfgrass.
Core technology:
Key performance findings:
Applications:
The technology is currently at Technology Readiness Level (TRL) 4–5, having completed laboratory validation of formulation stability and seed germination compatibility. Initial proof-of-concept work has demonstrated that dry coating formulations preserve Metarhizium viability and do not impair turfgrass seed germination. Future validation will include accelerated shelf-life testing (aging treated seeds for 7 to 28 days at 40°C), quantitative conidial viability assays following equilibration to optimal water activity, and refinement of coating processes to further minimize EPF exposure to water. The research leverages established cooperators across formulation chemistry, turfgrass entomology, and field crop pathology, positioning the technology for advancement toward field trials and commercial scale-up.
Cornell University is a comprehensive private, land-grant research university with campuses in Ithaca and New York City, combining significant scale with cross-disciplinary breadth. Industry connects through open-access user facilities and prototyping labs, pilot-scale testbeds, and a research and technology park that provide pathways from discovery to demonstration. A statewide extension network and integration with a major hospital system enable real-world deployment, while a graduate campus embedded in New York City’s tech corridor provides direct access to startups, venture investors, and corporate R&D teams. Research is supported by competitive federal funding from agencies such as the National Science Foundation, National Institutes of Health, the Department of Energy, and the U.S. Department of Agriculture. A dedicated technology transfer office streamlines IP management, licensing, startup formation, and corporate partnerships across campuses.